AIM ImmunoTech (NYSEAMERICAN:AIM) Shares to Split on Friday, January 9th

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM)’s stock is scheduled to split on Friday, January 9th. The 1001-1000 split was recently announced. The newly issued shares will be distributed to shareholders after the market closes on Thursday, January 8th.

AIM ImmunoTech Stock Performance

NYSEAMERICAN AIM opened at $1.19 on Monday. The firm’s fifty day moving average is $1.53 and its two-hundred day moving average is $3.47. AIM ImmunoTech has a one year low of $1.07 and a one year high of $36.00. The firm has a market cap of $3.39 million, a PE ratio of -0.06 and a beta of 1.21.

AIM ImmunoTech (NYSEAMERICAN:AIM) last announced its earnings results on Monday, November 17th. The company reported ($1.57) earnings per share for the quarter. The firm had revenue of $0.03 million for the quarter. Research analysts predict that AIM ImmunoTech will post -0.3 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Zacks Research lowered AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. One research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy”.

Institutional Trading of AIM ImmunoTech

An institutional investor recently bought a new position in AIM ImmunoTech stock. Sabby Management LLC bought a new stake in shares of AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 28,855 shares of the company’s stock, valued at approximately $79,000. AIM ImmunoTech comprises 0.1% of Sabby Management LLC’s investment portfolio, making the stock its 22nd largest position. Sabby Management LLC owned approximately 1.06% of AIM ImmunoTech at the end of the most recent quarter. 12.02% of the stock is currently owned by institutional investors.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.